706-1384

completed

Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease. · Phase II
706 (USA) · Dr. Rossi
consented 2012-09-15

AEs

Serious

Dropout signal

–

Adverse events

moderate assessed

Moderate ERYTHEMA — outcome: NOT RECOVERED/NOT RESOLVED; onset 2012-09-15 (study day 1.0); relationship: NONE

moderate assessed

Moderate ERYTHEMA — outcome: RECOVERED/RESOLVED; onset 2012-09-15 (study day 1.0); relationship: NONE

moderate assessed

Moderate ERYTHEMA — outcome: NOT RECOVERED/NOT RESOLVED; onset 2012-09-23 (study day 9.0); relationship: PROBABLE

moderate assessed

Moderate ERYTHEMA — outcome: RECOVERED/RESOLVED; onset 2012-09-23 (study day 9.0); relationship: PROBABLE

moderate assessed

Moderate EXCORIATION — outcome: NOT RECOVERED/NOT RESOLVED; onset 2012-09-15 (study day 1.0); relationship: NONE

moderate assessed

Moderate EXCORIATION — outcome: RECOVERED/RESOLVED; onset 2012-09-15 (study day 1.0); relationship: NONE

moderate assessed

Moderate PRURITUS — outcome: NOT RECOVERED/NOT RESOLVED; onset 2012-09-15 (study day 1.0); relationship: NONE

moderate assessed

Moderate PRURITUS — outcome: RECOVERED/RESOLVED; onset 2012-09-15 (study day 1.0); relationship: NONE

moderate assessed

Moderate PRURITUS — outcome: NOT RECOVERED/NOT RESOLVED; onset 2012-09-23 (study day 9.0); relationship: PROBABLE

moderate assessed

Moderate PRURITUS — outcome: RECOVERED/RESOLVED; onset 2012-09-23 (study day 9.0); relationship: PROBABLE

Data queries

No data queries.